Join the Advanced Therapies Community and the Regulatory Policy & Intelligence committee for a unique opportunity to sit down with FDA's Office of Pharmaceutical Policy.

This exclusive session will delve into cutting-edge quality policy topics that are rapidly shaping the future of the pharmaceutical industry, including advanced manufacturing, artificial intelligence in manufacturing, and more. As these innovative approaches redefine industry standards, understanding the FDA’s perspective on both the opportunities and challenges is more crucial than ever. Attendees will gain insight into the evolving regulatory landscape, learn about the application of the platform designation program from a CMC quality standpoint, and explore how emerging technologies are influencing product quality and patient safety. Don’t miss this rare chance to hear from FDA leaders on the forefront of pharmaceutical policy—an essential event for anyone eager to stay ahead in this dynamic field.